Actively Recruiting
Phase III Trial Comparing Low Dose Nivolumab Plus Standard Chemotherapy Versus Standard Chemotherapy Alone as First Treatment in Advanced or Metastatic Non-Small Cell Lung Cancer
Led by Dr Arvindran A/L Alaga · Updated on 2025-07-03
123
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of low dose Nivolumab combined with standard chemotherapy compared to standard chemotherapy alone in patients with locally advanced or metastatic non-small cell lung cancer NSCLC. This phase III randomized trial aims to determine whether adding low dose immunotherapy can improve outcomes for patients who have not received prior treatment for advanced disease. Participants will be randomly assigned in a 21 ratio to receive either low dose Nivolumab 40mg every six weeks plus standard chemotherapy or standard chemotherapy alone. Chemotherapy options include 4 to 6 cycles of Cisplatin or Carboplatin combined with Pemetrexed, Gemcitabine, Docetaxel, or Paclitaxel, administered according to local practice. The study treatment period will last several months based on chemotherapy cycles and immunotherapy dosing schedules. Throughout the trial, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests to monitor organ function, and patient-reported outcome questionnaires to assess quality of life. Researchers will track progression-free survival up to 36 months and monitor overall survival, adverse events, treatment discontinuations, and deaths related to treatment for up to 27 months. Follow-up visits and evaluations will continue to ensure safety and collect data on treatment effects over time.
CONDITIONS
Brief Title
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Research Team
D
Dr. Arvindran A/L Alaga
L
LEDANG Coordinating Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here